Transsion (688036) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
30 Oct, 2026Executive summary
Q3 revenue was RMB 14.85bn; attributable net income was RMB 856.6m, down 9.73% YoY, and adjusted net income was RMB 435.8m, down 47.72% YoY.
9M revenue rose 1.49% YoY to RMB 50.28bn; attributable net income increased 22.44% to RMB 2.63bn.
Financial highlights
9M total profit was RMB 3.29bn, up 21.91% YoY; net income attributable to shareholders was RMB 2.63bn, up 22.44%.
9M adjusted net income was RMB 1.92bn, up 10.70% YoY; Q3 adjusted net income was RMB 435.8m, down 47.72%.
Basic EPS was RMB 0.74 in Q3, down 9.76% YoY, and RMB 2.28 for 9M, up 21.28%.
9M R&D spending rose 15.90% to RMB 2.48bn; R&D was 4.93% of revenue, up 0.61 percentage points YoY.
Key financial ratios and metrics
Weighted average ROE was 4.03% in Q3, down 6.35 percentage points YoY; 9M ROE was 12.40%, up 1.92 percentage points.
Total assets were RMB 46.26bn at quarter-end, up 4.23% from year-end 2025; equity attributable to shareholders was RMB 21.05bn, up 2.55%.
Latest events from Transsion
- Revenue and profit fell sharply, but market leadership and high dividend were maintained.688036
Q4 2025 - Revenue up 10.31% to RMB 68.72B; net profit RMB 5.55B; Africa market share leads.688036
Q4 2024 - H1 2026 net profit jumped 46.22% year-over-year, with strong growth in emerging markets.688036
Q2 2026 - Revenue and net profit surged in Q1 2026, but operating cash flow turned negative.688036
Q1 2026 - Q3 revenue grew, but year-to-date profit dropped nearly 45% due to margin pressures.688036
Q3 2025 - Revenue and profit fell, but market leadership and high R&D investment were maintained.688036
Q2 2025 - Q3 profit and margins fell sharply despite higher YTD revenue and increased R&D investment.688036
Q3 2024 - Revenue and net profit surged over 35% year-over-year, with Africa market share above 40%.688036
Q2 2024 - Revenue and profit plunged in Q1 2025 amid fierce competition and cost pressures.688036
Q1 2025